<DOC>
	<DOC>NCT01073228</DOC>
	<brief_summary>This study is being conducted to determine the safety and effect on cognitive function of the investigational medication, EVP-6124, in individuals with mild to moderate probable Alzheimer's disease.</brief_summary>
	<brief_title>Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease</brief_title>
	<detailed_description>This is a randomized, double-blind, placebo-controlled, parallel, 24-week, Phase 2 safety/efficacy study in which three dose levels of EVP-6124 or placebo will be evaluated. Eligible for enrollment will be patients who meet clinical criteria for mild to moderate probable Alzheimer's disease who are either receiving treatment with AChEI medication at a stable dose or who are not presently taking any AChEI or memantine co-medication. Patients will be randomized to one of the following groups: 0.3 mg, 1 mg or 2 mg or Placebo. Approximately 400 subjects will be randomized to the 4 treatment groups. Study drug will be supplied as capsules and will be orally administered once daily for a total of 24 weeks.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Nicotinic Agonists</mesh_term>
	<criteria>Subjects with Probable Alzheimer's disease MiniMental State Examination (MMSE) score of 14 to 24 inclusive at screening and a CDRSB score ≥2 at the screening assessment Modified Hachinski Ischemic Score (mHIS) ≤4 at screening Female subjects are ≥1 year postmenopausal or are surgically sterile Caregiver available; if not living in the same household, caregiver sees subject at least four times each week Subject living at home, senior residential setting, or an institutional setting without the need for continuous nursing care General health status acceptable for participation in a 24 week clinical trial be administered General Participation in another therapeutic clinical trial within 30 days before Baseline Prior participation in an amyloid vaccination clinical study Inability to swallow capsules Likely inability to complete 24 week study Inability to be ≥75% compliant with singleblind placebo runin medication Inability to adequately perform cognitive tests History of significant cardiovascular disease Major depression Psychosis History of stroke within 18 months of screening Head trauma Inability to perform any screening or baseline evaluations</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>Central Nervous System diseases</keyword>
	<keyword>Cognition</keyword>
</DOC>